Literature DB >> 1356053

Chromogranin A as tumor marker in medullary thyroid carcinoma.

E Blind1, H Schmidt-Gayk, H P Sinn, D T O'Connor, F Raue.   

Abstract

We measured plasma levels of chromogranin A (CgA) and calcitonin (CT) in 61 patients with surgically confirmed medullary thyroid carcinoma (MTC). CT was elevated in 46 patients, whereas CgA was elevated in 14 patients. Plasma levels of CgA and CT were moderately correlated (r = 0.87), but CgA became elevated in most patients only in advanced disease. Patients with high plasma CT values (greater than 10 micrograms/L) also had elevated CgA in 83% of cases. An elevated plasma CgA level despite normal CT levels was found in only 1 patient. In 8 MTC patients with moderately elevated basal CT levels, pentagastrin as a secretagogue usually was not able to release detectable amounts of CgA from MTC tissue. In 2 MTC patients, i.v. catheter sampling gave sharp gradients for CT concentrations (greater than 2.7-fold peak to peripheral ratios) and, therefore, precise MTC tissue localization, whereas no gradients were demonstrable for CgA (less than 1.2-fold). One patient with MTC and elevated CgA reached normal CgA plasma levels within 8 days after thyroidectomy. In metastatic tissue from 8 patients with MTC, CgA and CT were detectable immunohistologically in all cases, but plasma CgA was elevated only in 2 and CT in 7 of them. Plasma CgA levels in patients with MTC usually became elevated only in advanced disease and were not able to detect early disease stages, were correlated with CT levels, were not useful in stimulation tests or venous localization studies, and probably resulted from the release from MTC tissue as the major tissue source, as shown in the sporadic cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356053     DOI: 10.1089/thy.1992.2.5

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

Authors:  Shaohua Zhan; Jinming Li; Tianxiao Wang; Wei Ge
Journal:  Oncologist       Date:  2018-05-08

2.  Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone.

Authors:  A J Mixson; P Hauser; G Tennyson; J C Renault; D L Bodenner; B D Weintraub
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

3.  Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis.

Authors:  Viola Melone; Annamaria Salvati; Domenico Palumbo; Giorgio Giurato; Giovanni Nassa; Francesca Rizzo; Luigi Palo; Alessandro Giordano; Mariarosaria Incoronato; Mario Vitale; Caterina Mian; Immacolata Di Biase; Stefano Cristiano; Viviana Narciso; Monica Cantile; Annabella Di Mauro; Fabiana Tatangelo; Salvatore Tafuto; Roberta Modica; Claudia Pivonello; Marco Salvatore; Annamaria Colao; Alessandro Weisz; Roberta Tarallo
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

Review 4.  The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases.

Authors:  A O Vladutiu
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

5.  Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma.

Authors:  L Guignat; J M Bidart; M Nocera; E Comoy; M Schlumberger; E Baudin
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

6.  A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.

Authors:  G P Bernini; A Moretti; M Ferdeghini; S Ricci; C Letizia; E D'Erasmo; G F Argenio; A Salvetti
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

Review 7.  Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.

Authors:  Xin Yang; Yuan Yang; Zhilu Li; Chen Cheng; Ting Yang; Cheng Wang; Lin Liu; Shengchun Liu
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 8.  Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis.

Authors:  Peng Hong; Run-Qi Guo; Gang Song; Kai-Wei Yang; Lei Zhang; Xue-Song Li; Kai Zhang; Li-Qun Zhou
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

Review 9.  Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.

Authors:  Sushil K Mahata; Angelo Corti
Journal:  Ann N Y Acad Sci       Date:  2019-10-06       Impact factor: 5.691

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.